|
AVL9 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.61769999999751E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.414800E-04 |
| Normal-vs-Stage2 |
1.880540E-03 |
| Normal-vs-Stage3 |
7.011800E-04 |
| Normal-vs-Stage4 |
7.449000E-04 |
| Stage1-vs-Stage2 |
7.892200E-01 |
| Stage1-vs-Stage3 |
8.543800E-01 |
| Stage1-vs-Stage4 |
6.918400E-01 |
| Stage2-vs-Stage3 |
9.080600E-01 |
| Stage2-vs-Stage4 |
9.247200E-01 |
| Stage3-vs-Stage4 |
8.203600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.649600E-04 |
| Normal-vs-AfricanAmerican |
8.548300E-02 |
| Normal-vs-Asian |
1.037040E-04 |
| Caucasian-vs-AfricanAmerican |
4.988800E-01 |
| Caucasian-vs-Asian |
2.644000E-01 |
| AfricanAmerican-vs-Asian |
1.664240E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.56120000044591E-07 |
| Normal-vs-Female |
8.837300E-04 |
| Male-vs-Female |
2.636100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.538300E-03 |
| Normal-vs-Age(41-60Yrs) |
4.06310000000687E-05 |
| Normal-vs-Age(61-80Yrs) |
5.445900E-04 |
| Normal-vs-Age(81-100Yrs) |
6.620200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.179000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.490400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.693800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.651200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.385000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.808400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.347200E-01 |
| Classical-VS-Follicular |
1.416620E-03 |
| Classical-VS-Other |
8.206300E-02 |
| Classical-VS-Normal |
3.104700E-03 |
| Tall-VS-Follicular |
1.796190E-01 |
| Tall-VS-Other |
1.053410E-01 |
| Tall-VS-Normal |
5.899100E-03 |
| Follicular-VS-Other |
5.287200E-01 |
| Follicular-VS-Normal |
1.84569999994721E-06 |
| Other-VS-Normal |
2.278200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.05549999999777E-05 |
| Normal-vs-N1 |
1.117100E-03 |
| N0-vs-N1 |
9.655200E-01 |
|
|
